Nitro-benzamide useful as anti-arrhythmic agent
CA 2285197 A1 · Owner: Slater, Graham Ralph · Inventors: Slater, Graham Ralph; Westlake, Paul Jeffrey
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Hydrated N-3-2-(3,4-dimethoxyphenyl)ethylaminopropyl-4-nitro benzamide hydrochloride characterised in that it: (i) comprises water in the range of from 1.7 to 2.4 molar equivalents; and/or (ii) has a melting point above 145 ~C and/or, (iii) provides an infra red spectrum containing peaks at 3510 3342, 3076, 1665, 1598, 1343, 1330, 1216 and 801 cm-1; and/or (iv) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as represented in Table I; and/or (v) provides an X-ray powder refraction (XRPD) pattern substantially as represented in Table II; a process for preparing such a compound, a pharmaceutical composition comprising such a compound …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 24, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 24, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 24, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.